Dabrafenib and trametinib versus dabrafenib and placebo for Val600 BRAF-mutant melanoma: a multicentre, double-blind, phase 3 randomised controlled trial
Georgina Venetia Long, Daniil Stroyakovskiy, Helen J Gogas et al. · The Lancet · 2015
Cited by 1,399 works. doi:10.1016/s0140-6736(15)60898-4
Authors
- Georgina Venetia Long
- Daniil Stroyakovskiy
- Helen J Gogas
- E. Levchenko
- Filippo de Braud
- James Larkin
- Claus Garbe
- Thomas Jouary
- Axel Hauschild
- Jean‐Jacques Grob
- Vanna Chiarion‐Sileni
- Célèste Lebbé
- Mario Mandalà
- Michael Millward
- Ana Maria Arance
- Igor Bondarenko
- John B.A.G. Haanen
- Johan Hansson
- Jochen Sven Utikal
- Virginia Ferraresi
References
- New response evaluation criteria in solid tumours: Revised RECIST guideline (version 1.1)
- A Multiple Testing Procedure for Clinical Trials
- Improved Survival with Ipilimumab in Patients with Metastatic Melanoma
- Discrete Sequential Boundaries for Clinical Trials
- Nivolumab in Previously Untreated Melanoma without BRAF Mutation
- Pembrolizumab versus Ipilimumab in Advanced Melanoma
- Combined BRAF and MEK Inhibition in Melanoma with BRAF V600 Mutations
- Improved Overall Survival in Melanoma with Combined Dabrafenib and Trametinib
- Combined Vemurafenib and Cobimetinib in BRAF -Mutated Melanoma
- Combined BRAF and MEK Inhibition versus BRAF Inhibition Alone in Melanoma